Muscle Carnitine Palmitoyltransferase Deficiency (ICD-10-CM Code: E71.314)

Name of the Condition

• Muscle carnitine palmitoyltransferase deficiency.

Summary

Muscle carnitine palmitoyltransferase deficiency is an inherited metabolic disorder that impairs the body's ability to break down long-chain fatty acids for energy, particularly in muscle tissue. This can lead to the accumulation of toxic byproducts during fasting, exercise, or illness, resulting in symptoms affecting muscle function. The condition disrupts normal metabolic pathways, potentially causing energy deficits or muscle damage if untreated.

Causes

This disorder is caused by genetic mutations that affect the carnitine palmitoyltransferase enzyme, which is essential for fatty-acid oxidation. Most cases are inherited in an autosomal recessive pattern, meaning both parents must carry a mutated gene for a child to be affected. The specific genetic defect determines the severity and clinical presentation of the condition.

Risk Factors

• Family history of fatty-acid oxidation disorders.
• Consanguineous relationships (parents who are closely related).
• Certain ethnic populations with higher carrier rates for specific mutations.

Symptoms

• Muscle weakness or pain, especially during exercise or fasting.
• Myoglobinuria (dark urine due to muscle breakdown).
• Fatigue or lethargy.
• Muscle cramps or stiffness.
• In severe cases, rhabdomyolysis (rapid muscle breakdown).

Diagnosis

Diagnosis typically involves clinical evaluation of symptoms, followed by laboratory tests to assess muscle enzymes (e.g., creatine kinase) and metabolic function. Genetic testing may confirm the presence of mutations in the carnitine palmitoyltransferase gene. Additional tests, such as muscle biopsy or exercise challenge tests, may be used to assess enzyme activity.

Treatment Options

Treatment focuses on managing symptoms and preventing complications. This may include avoiding prolonged fasting or intense exercise, maintaining a balanced diet with adequate carbohydrates, and in some cases, supplementing with carnitine. Severe episodes may require hospitalization for hydration and monitoring.

Prognosis and Follow-Up

Prognosis varies depending on the severity of the condition. With proper management, many individuals can lead active lives, but severe cases may experience recurrent muscle damage. Regular follow-up with a metabolic specialist is recommended to monitor symptoms and adjust treatment as needed.

Complications

• Recurrent rhabdomyolysis.
• Kidney damage from myoglobin release.
• Chronic muscle weakness or pain.
• Exercise intolerance.

Lifestyle & Prevention

• Avoid prolonged fasting or strenuous exercise without adequate nutrition.
• Maintain a diet rich in carbohydrates to support energy needs.
• Stay hydrated, especially during physical activity.
• Inform healthcare providers about the condition before undergoing medical procedures or surgeries.

When to Seek Professional Help

Seek immediate medical attention if you experience severe muscle pain, dark urine, or signs of rhabdomyolysis. Consult a healthcare provider for persistent muscle weakness, fatigue, or if symptoms worsen during illness or fasting.

Tips for Medical Coders

When coding for muscle carnitine palmitoyltransferase deficiency, use ICD-10-CM code E71.314. Ensure documentation supports the diagnosis, including clinical symptoms, diagnostic test results, and genetic confirmation if available. Note any associated complications or treatment plans to support accurate coding.